Physician profile
Gregory Amend
NPI 1588076798
$89,114.70
in general payments reported to CMS, 2019-2025
14 companies · $50K in 2025
The $50K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $91.03 · 2021: $667 · 2022: $2,261 · 2023: $2,376 · 2024: $33K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $41K · Education: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $10K · Travel and Lodging: $7,150 · Gift: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $41,011.02 |
| Education | $15,035.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,275.00 |
| Food and Beverage | $10,140.06 |
| Travel and Lodging | $7,150.48 |
| Gift | $151.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $67,739.20 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Boston Scientific Corporation | $14,863.01 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, Ams 700, General - Erectile Dysfunction |
| Coloplast Corp | $5,803.88 | 2021-2025 | Titan, Virtue, Wilson |
| Urogen Pharma, INC. | $158.93 | 2025 | |
| Access Pro Medical, LLC | $150.02 | 2025 | Matriderm |
| Pfizer INC. | $103.87 | 2019 | |
| Progenics Pharmaceuticals, INC. | $86.13 | 2023-2025 | Pylarify |
| Sumitomo Pharma America, INC. | $58.42 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Antares Pharma, INC. | $28.16 | 2024 | Xyosted |
| Endo USA, INC. | $24.29 | 2024 | Xiaflex, Edex, Aveed |
| Blue Earth Diagnostics | $23.47 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $21.02 | 2022 | |
| Merck Sharp & Dohme LLC | $19.24 | 2024 | Welireg, Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Amend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.